Hot Medical Stocks To Buy Right Now

Big changes are under way right now in our neighbor to the north. Beginning Oct. 17, recreational marijuana will officially go on sale in Canada, making it the first industrialized country in the world to give adult-use weed the green light.

The legalization of marijuana in Canada is expected to generate up to $5 billion in annual sales once the industry is fully up to speed. Though some of this revenue will come from domestic markets, Canadian growers are angling to reap significant rewards from exports since roughly 30 countries having legalized medical cannabis to some degree. However, the United States won’t be one of those countries.

Image source: Getty Images.

The U.S. federal government stymies cannabis progress

Whereas most of the developed world appears to be progressing on their view of cannabis, the U.S. has remained stuck in neutral. Even though Oklahoma recently became the 30th state to have legalized medical marijuana in some capacity, the federal government has held firm on its stance that cannabis is a Schedule I substance. According to the Controlled Substances Act, that means marijuana is entirely illegal, prone to abuse, and devoid of any recognized medical benefits.

Hot Medical Stocks To Buy Right Now: Equinix Inc.(EQIX)

Advisors’ Opinion:

  • [By Lee Jackson]

    This is one of the larger capitalization companies in the data center industry. Equinix Inc. (NASDAQ: EQIX) provides data center services to protect and connect the information assets for the enterprises, financial services companies, and content and network providers primarily in the Americas, Europe, the Middle East, Africa and the Asia-Pacific.

  • [By Stephan Byrd]

    Credit Suisse Group set a $525.00 price objective on Equinix (NASDAQ:EQIX) in a research report report published on Friday. The firm currently has a buy rating on the financial services provider’s stock.

  • [By Beth McKenna]

    Equinix (NASDAQ:EQIX) reported robust first-quarter 2018 financial results after the market close on Wednesday. 

    Shares closed down 6.1% on Thursday, which we can probably attribute to the company revising slightly downward its full-year 2018 adjusted funds from operations (AFFO) outlook, as we’ll get to in a moment. (AFFO is a closely watched metric for companies organized as real estate investment trusts, or REITs. It’s akin to “earnings” for REITs.) 

Hot Medical Stocks To Buy Right Now: Harte-Hanks, Inc.(HHS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Bioblast Pharma Ltd. (NASDAQ: ORPN) shares rose 29.6 percent to $3.22.
    Mannatech, Incorporated (NASDAQ: MTEX) surged 23.3 percent to $19.60 after the company reported commencement of modified Dutch auction cash tender for up to $16 million of common stock.
    Evolus, Inc. (NASDAQ: EOLS) shares rose 22.1 percent to $15.8003.
    Quotient Limited (NASDAQ: QTNT) gained 18.1 percent to $5.54 following commencement of EU blood grouping field trial.
    Shineco, Inc. (NASDAQ: TYHT) climbed 17.1 percent to $1.9899 following Q3 results. Shineco posted Q3 earnings of $0.21 per share on sales of $13.3 million.
    CPI Card Group Inc. (NASDAQ: PMTS) rose 17 percent to $3.0999.
    Dover Downs Gaming & Entertainment, Inc. (NYSE: DDE) shares climbed 12 percent to $2.2613. The stock spiked more than 14 percent Thursday near the close as traders circulate word the Delaware lottery is planning to introduce full sports betting in June.
    Harte Hanks, Inc. (NYSE: HHS) shares gained 7.2 percent to $11.05 after the company late Thursday appointed four new independent directors to board.
    Cronos Group Inc. (NASDAQ: CRON) rose 6.4 percent to $6.17.
    VivoPower International PLC (NASDAQ: VVPR) shares gained 6.3 percent to $3.74.
    Global Self Storage, Inc. (NASDAQ: SELF) shares climbed 6 percent to $4.20.

    Check out these big penny stock gainers and losers

  • [By Ethan Ryder]

    ValuEngine upgraded shares of Harte Hanks (NYSE:HHS) from a sell rating to a hold rating in a research report sent to investors on Monday.

    HHS has been the topic of a number of other reports. Noble Financial reaffirmed a buy rating on shares of Harte Hanks in a research note on Monday, March 5th. Zacks Investment Research raised shares of Harte Hanks from a hold rating to a strong-buy rating and set a $12.00 target price on the stock in a research note on Tuesday, May 15th.

  • [By Logan Wallace]

    These are some of the news stories that may have effected Accern’s rankings:

    Get Harte Hanks alerts:

    Harte-Hanks (HHS) Name Four New Independent Directors (streetinsider.com) Harte Hanks (HHS) Given $15.00 Consensus Price Target by Brokerages (americanbankingnews.com) Harte Hanks to Appoint Four New Independent Directors to the Board (feeds.benzinga.com) Harte Hanks (HHS) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com) Harte Hanks (HHS) Shares March Higher, Can It Continue? (zacks.com)

    Shares of Harte Hanks traded up $0.65, reaching $10.96, during trading hours on Friday, according to Marketbeat.com. The stock had a trading volume of 46,930 shares, compared to its average volume of 18,474. Harte Hanks has a 12 month low of $7.30 and a 12 month high of $14.40. The stock has a market capitalization of $64.54 million, a price-to-earnings ratio of -9.13 and a beta of 0.90.

  • [By Ethan Ryder]

    ValuEngine upgraded shares of Harte Hanks (NYSE:HHS) from a strong sell rating to a sell rating in a research report report published on Friday morning.

  • [By Logan Wallace]

    Noble Financial reissued their buy rating on shares of Harte Hanks (NYSE:HHS) in a report issued on Thursday.

    HHS has been the topic of a number of other research reports. ValuEngine upgraded shares of Harte Hanks from a strong sell rating to a sell rating in a report on Tuesday, August 28th. Zacks Investment Research cut shares of Harte Hanks from a hold rating to a strong sell rating in a report on Tuesday, August 14th.

Hot Medical Stocks To Buy Right Now: Durect Corporation(DRRX)

Advisors’ Opinion:

  • [By Brian Orelli]

    DURECT Corp. (NASDAQ:DRRX) is down 9.2% at 12:45 p.m. EDT after the U.S. Food and Drug Administration’s advisory committee voted 14 to 3 recommending the agency not approve Remoxy ER, an abuse-deterrent extended-release pain medication being developed by its partner Pain Therapeutics (NASDAQ: PTIE).

  • [By Shane Hupp]

    Headlines about DURECT (NASDAQ:DRRX) have been trending somewhat positive on Friday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. DURECT earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 47.6857828380145 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on DURECT (DRRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on DURECT (DRRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Medical Stocks To Buy Right Now: American Airlines Group, Inc.(AAL)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage loss in the S&P 500 ahead of the close was American Airlines Group Inc. (NASDAQ: AAL) which fell about 8% to $36.00. The stock’s 52-week range is $35.90 to $59.08. Volume was 24 million compared to the daily average volume of 6.2 million.

  • [By Chris Dier-Scalise]

    More evidence of strength in the contractors can be seen in a uptick in both government and private contracts. Boeing might be winner of the most high-profile and sizable agreements, recently winning both a $3.9 billion contract to modernize the Air Force One fleet as well as a deal with American Airlines Group Inc (NYSE: AAL) for 47 planes valued at $12 billion.

  • [By Lisa Levin]

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Before the markets open, Bristol-Myers Squibb Company (NYSE: BMY) is projected to report quarterly earnings at $0.85 per share on revenue of $5.24 billion. Bristol-Myers shares rose 0.95 percent to $52.25 in after-hours trading.
    AT&T Inc. (NYSE: T) reported weaker-than-expected earnings

  • [By Adam Levine-Weinberg]

    Not surprisingly, the airlines with the lowest profit margins have been hit hardest. These carriers are the most vulnerable to fuel price increases and demand shocks, as small changes in their profit margins can severely impact their earnings. During the past year, American Airlines (NASDAQ:AAL) has fallen into the bottom echelon of U.S. airlines in terms of profitability, and so its share price tumbled 7.5% in the first three days of this week.

Hot Medical Stocks To Buy Right Now: Hibbett Sports Inc.(HIBB)

Advisors’ Opinion:

  • [By Shane Hupp]

    Trexquant Investment LP acquired a new stake in shares of Hibbett Sports (NASDAQ:HIBB) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 12,159 shares of the company’s stock, valued at approximately $291,000.

  • [By Shane Hupp]

    Canaccord Genuity downgraded shares of Hibbett Sports (NASDAQ:HIBB) from a buy rating to a hold rating in a research report released on Monday, MarketBeat.com reports. The firm currently has $21.00 target price on the stock, down from their prior target price of $31.00.

  • [By Dan Caplinger]

    Wall Street had a major celebration on Friday, as the S&P 500 finished at an all-time high for the first time in roughly seven months. Investors generally pointed to Federal Reserve Chairman Jerome Powell’s comments that suggested that a gradual pace of future interest rate increases was the most likely scenario for the U.S. credit markets. The prospects for predictable monetary policy moves was a positive for the market overall, but there were still some companies that dealt with specific bad news that hurt their individual stock prices. Foot Locker (NYSE:FL), Hibbett Sports (NASDAQ:HIBB), and Grupo Supervielle (NYSE:SUPV) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Motley Fool Transcribers]

    Hibbett Sports Inc (NASDAQ:HIBB)Q2 2019 Earnings Conference CallAug. 24, 2018, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Ethan Ryder]

    Hibbett Sports, Inc. (NASDAQ:HIBB) has received a consensus rating of “Hold” from the nineteen research firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $21.23.

  • [By Lisa Levin]

    Breaking news

    Foot Locker, Inc. (NYSE: FL) reported better-than-expected results for its first quarter.
    Hibbett Sports, Inc. (NASDAQ: HIBB) reported weaker-than-expected results for its first quarter.
    Ross Stores, Inc. (NASDAQ: ROST) reported upbeat earnings for its first quarter, but issued weak forecast for the current quarter.
    Gap Inc (NYSE: GPS) posted downbeat earnings for its first quarter on Thursday. Comps were up 1 percent in the quarter.

Leave a Reply

Your email address will not be published. Required fields are marked *